Cannabis and O-1602
Browse the latest research linking medical marijuana / medicinal cannabis and O-1602 (a cannabinoid (synthetic))

Action: GPR18,GPR55
O-1602 does not bind to the classical cannabinoid receptors CB1 or CB2 with any significant affinity, but instead is an agonist at several other receptors which appear to be related to the cannabinoid receptors, particularly GPR18 and GPR55. [Wikipedia]
Click on a study title below to open a new tab with full article, or click on a compound to see it's full list of research.
Compounds Topics Title Date
O-1602,Abn-CBD diabetes in mice via experiment G-protein coupled receptor 55 agonists increase insulin secretion through inositol trisphosphate-mediated calcium release in pancreatic beta--cells Apr 2019
Action Pathway: GPR55
Our results demonstrated that O-1602 and Abn-CBD increased glucose-induced insulin secretion in MIN6 cells, which was abolished by a PLC inhibitor, U73122.
O-1602 gvhd in vitro A CB2-Selective Cannabinoid Suppresses T-cell Activities and Increases Tregs and IL-10 May 2015
These data support the potential of CB2-selective agonists as useful therapeutic agents to prolong graft survival in transplant patients, and strengthens their potential as a new class of immunosuppressive agents with broader applicability.
Back to Knowledge Base